Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-000595
Filing Date
2025-01-03
Accepted
2025-01-03 17:31:21
Documents
1
Period of Report
2025-01-02

Document Format Files

Seq Description Document Type Size
1 form4-01032025_100118.html 4  
1 form4-01032025_100118.xml 4 6206
  Complete submission text file 0001415889-25-000595.txt   7656
Mailing Address 350 FIFTH AVENUE, SUITE 7530 NEW YORK NY 10118
Business Address
Alam Kamran (Reporting) CIK: 0001793412 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39536 | Film No.: 25508068

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Issuer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)